Navigation Links
A new development in the relief of spasms related to amyotrophic lateral sclerosis
Date:11/6/2012

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with an occurrence rate in France similar to multiple sclerosis (two to three new cases per year for every 100,000 residents). It has a specific affect on neurons responsible for motor control, in particular motor neurones and central motor neurones. The former, located in the spinal cord, are directly linked to muscles and are used for muscle contraction and stretching. The latter, located in the brain, receive movement orders. As the disease develops, the neurons degenerate and the muscles are no longer stimulated and stop working. Movements, walking and speech become increasingly difficult and patients tend to pass away an average of two to five years after diagnosis, generally due to respiratory failure.

Paralysis is accompanied by other symptoms, which can be highly disabling on a daily basis. Spasms (or spasticity) are an exaggerated muscular response to a stimulus; they produce long and involuntary muscle contractions, coupled with pain. Spasticity is frequently observed in ALS. Until now, it was attributed to the loss of central motor neurons.

In this study, Inserm researchers have shown that these spasms are, in fact, linked to the degeneration of another type of serotonin-producing neurons located on the brain.

They have observed - both in patients with ALS and in a transgenic mouse model - that serotonergic neurons waste away as the disease develops and that serotonin levels in the spinal cord sharply decreased before the motor-related symptoms appeared.

Furthermore, some molecules active against serotonin receptors eliminate spasms in transgenic mice suffering from ALS. This research demonstrates that neuron degeneration in ALS is not limited to the motor system in its strictest sense. For Luc Dupuis "molecules acting on serotonin receptors 5-HT2B and C could be antispastic for ALS patients over the long-term".


'/>"/>
Contact: press
presse@inserm.fr
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert

Page: 1

Related medicine news :

1. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
2. Kudos for 3 NJIT Enterprise Development Center high-tech companies
3. 2 repressor genes identified as essential for placental development
4. Louisiana Tech University professor earns NSF Early Career Development grant
5. Advanced genetic screening method may speed vaccine development
6. New biospecimens management system in development
7. Developmental Woes Common in Siblings of Children With Autism
8. Mutations impair childhood growth and development by disrupting organization of chromosome pairs
9. Penn and Cornell researchers spearhead the development of new guidelines for veterinary CPR
10. Study sheds new light on role of genetic mutations in colon cancer development
11. The first day of development -- a window to successful pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Explorys, the leader in big data-driven healthcare transformation, ... Yarrington as Vice President of Operations, Adam Wallace as ... President of Solutions. These new leaders are part of ... to support client demand for the company’s big data ... of its partner network. , Since the company ...
(Date:12/22/2014)... Give a loved one the greatest gift of ... vitality. , For a limited time, HealthiPlus ( https://healthiplus.com/christmas-gift-packages/ ... special Holiday Wellness gift packages at drastically reduced prices ... contains cutting-edge, proven nutritional support for joints, mental functioning ... we age. , Joint Health Plus contains ...
(Date:12/22/2014)... December 22, 2014 The MedTech industry is ... a wholly owned subsidiary of PartnerTech AB of Sweden, is ... recently achieved additional ISO Certification. , All signs point to ... and the likelihood of a repeal of the excise tax ... The industry is anticipating annual growth of 9.3% and PartnerTech ...
(Date:12/22/2014)... New York NY (PRWEB) December 22, 2014 ... reports that a federal panel of judges has granted ... lawsuits in the U.S. District Court, Eastern District ... (JPML) issued an order on December 12 to transfer ... actions–pending in 22 districts to the Louisiana court for ...
(Date:12/22/2014)... December 22, 2014 TheHardwareCity.com now stocks ... with many useful features. Customers of the large online ... the new gloves delivered to their home or workplace ... hand tools that incorporate heavy duty magnets, which make ... allows workers to store metal parts on the back ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2
... in the international research consortium named MetaHit, scientists from ... an individual,s intestinal bacteria flora, regardless of nationality, gender ... of intestinal bacteria flora is hypothesised to have an ... and medicine absorbed through the gastro-intestinal tract. The results ...
... , WEDNESDAY, April 20 (HealthDay News) -- Poor ... more likely than others to cut back on health ... to a new study. Conducted by the RAND ... earlier studies, which found that so-called "medically vulnerable" people ...
... Queen,s University professor Kate Harkness has found that a ... substantially increases the risk of depression in adolescence by ... Adolescents with a history of maltreatment and a mild ... of the stress hormone cortisol than is normal in ...
... Men are more likely to see issues in black-and-white, whereas women ... contends. British researchers asked 113 volunteers to judge how 50 ... The objects and categories were highly likely to stimulate debate or ... a tool? Men were found to be more likely to ...
... School of Medicine researcher has developed a potential ... prevalent sexually transmitted disease and the leading cause ... Ph.D., professor of immunology and microbiology, internal medicine ... demonstrated a vaccine effect to inoculate against Chlamydia ...
... of severe traumatic brain injury (TBI), the U.S. Department ... this type of injury receive adequate protein and calories ... weeks of treatment, says a new report from the ... severely brain-injured patients shows that providing energy and protein ...
Cached Medicine News:Health News:What's your intestinal bacteria type? 2Health News:High-Deductible Health Plans Bring Equal Savings to All: Study 2Health News:WSU files for patent on researcher's vaccine technology for chlamydia 2Health News:WSU files for patent on researcher's vaccine technology for chlamydia 3Health News:WSU files for patent on researcher's vaccine technology for chlamydia 4Health News:Protein and calories can help lessen effects of severe traumatic brain injury 2
(Date:12/19/2014)... 2014 In today,s rapidly changing, highly ... tools are essential for survival. The world is ... desires, preferences, and unmet needs are evolving rapidly. ... across all industries are continually searching for innovative ... adoption of new market research techniques like mobile ...
(Date:12/19/2014)... Somewhere between dropping five pounds and cooking ... Audicus , a next-generation hearing aids company, will ... Hearing loss is the third most common ... is often unaddressed. Forty-eight million Americans have hearing loss, ... mainly due to price. Hearing aids traditionally cost $7,000 ...
(Date:12/19/2014)... Dec. 18, 2014 Capnia, Inc. (NASDAQ: ... of medical diagnostics based on its proprietary Sensalyze™ ... today announced financial results for the third quarter ... "Following the completion of our initial public ... maximize the recently initiated CoSense® commercial launch," said ...
Breaking Medicine Technology:Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Audicus Will Help People Resolve to Hear Better in 2015 2Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8
... Pharmaceuticals, Inc. (NASDAQ: AUXL ), a ... data from the Collagenase Optimal Reduction of Dupuytren,s ... XIAFLEX ® (collagenase clostridium histolyticum) in the ... palpable cord. This five year observational study was ...
... Company remains committed to speeding innovation to ... boasts 70 potential medicines in clinical development, including 33 in Phases ... potential new medicines in Phase III by the end of 2011, ... as neuroscience, diabetes and oncology, as well as new areas such ...
Cached Medicine Technology:Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 2Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 3Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 4Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 5Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 6Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 7Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 8Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 9Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 2Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 3Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 4Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 5Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 6Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 7Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 8Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 9Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 10Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 11Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 12Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 13Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 14Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 15Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 16
For the direct colorimetric determination of alkaline phosphatase in human serum....
Auto LDL-Cholesterol, automated analyzer test kits....
For the quantitative determination of uric acid in serum....
For the quantitative determination of uric acid in serum....
Medicine Products: